Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Grading the new US Preventive Services Task Force prostate cancer screening recommendation.

Volk RJ, Wolf AM.

JAMA. 2011 Dec 28;306(24):2715-6. doi: 10.1001/jama.2011.1893. No abstract available.

PMID:
22203540
2.

Missing the mark on prostate-specific antigen screening.

Miller DC, Hollenbeck BK.

JAMA. 2011 Dec 28;306(24):2719-20. doi: 10.1001/jama.2011.1879. No abstract available.

PMID:
22203542
3.

Prostate cancer screening--time to abandon one-size-fits-all approach?

Kim J, Davis JW.

JAMA. 2011 Dec 28;306(24):2717-8. doi: 10.1001/jama.2011.1881. No abstract available.

PMID:
22203541
4.

Prostate cancer screening--the evidence, the recommendations, and the clinical implications.

Chou R, LeFevre ML.

JAMA. 2011 Dec 28;306(24):2721-2. doi: 10.1001/jama.2011.1891. No abstract available.

PMID:
22203543
5.

USPSTF finds little evidence to support advising PSA screening in any man.

Slomski A.

JAMA. 2011 Dec 21;306(23):2549-51. doi: 10.1001/jama.2011.1804. No abstract available.

PMID:
22187266
6.

Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.

Schröder FH.

N Engl J Med. 2011 Nov 24;365(21):1953-5. doi: 10.1056/NEJMp1112140. Epub 2011 Oct 26. No abstract available.

7.

Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.

Brett AS, Ablin RJ.

N Engl J Med. 2011 Nov 24;365(21):1949-51. doi: 10.1056/NEJMp1112191. Epub 2011 Oct 26. No abstract available.

8.

The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--point.

Ablin RJ.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):391-4. doi: 10.1158/1055-9965.EPI-12-0058. Epub 2012 Feb 7. No abstract available.

9.

2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.

Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE.

JAMA. 2012 Apr 25;307(16):1692-4. doi: 10.1001/jama.2012.534. No abstract available.

PMID:
22535850
10.

A piece of my mind. Making the call.

Welch HG.

JAMA. 2011 Dec 28;306(24):2649-50. doi: 10.1001/jama.2011.1898. No abstract available.

PMID:
22203530
11.

Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.

Cohn JA, Wang CE, Lakeman JC, Silverstein JC, Brendler CB, Novakovic KR, McGuire MS, Helfand BT.

Urol Oncol. 2014 Jan;32(1):41.e23-30. doi: 10.1016/j.urolonc.2013.04.013. Epub 2013 Aug 2.

PMID:
23911680
12.

One man at a time--resolving the PSA controversy.

McNaughton-Collins MF, Barry MJ.

N Engl J Med. 2011 Nov 24;365(21):1951-3. doi: 10.1056/NEJMp1111894. Epub 2011 Oct 26. No abstract available.

13.

Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.

Kwiatkowski M, Klotz L, Hugosson J, Recker F.

Eur Urol. 2012 Apr;61(4):851-4. doi: 10.1016/j.eururo.2012.01.023. Epub 2012 Jan 24. No abstract available.

PMID:
22285762
14.

Preventive Services Task Force recommends against PSA screening after age 75.

Twombly R.

J Natl Cancer Inst. 2008 Nov 19;100(22):1571-3. doi: 10.1093/jnci/djn422. Epub 2008 Nov 11. No abstract available.

15.

The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing.

Messing EM, Albertsen P, Andriole GL Jr, Carroll PR, Klein EA.

Urol Oncol. 2012 Jan-Feb;30(1):117-9. doi: 10.1016/j.urolonc.2011.12.010. No abstract available.

PMID:
22243597
16.

Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.

Makovey I, Stephenson AJ, Haywood S.

Curr Urol Rep. 2013 Jun;14(3):168-73. doi: 10.1007/s11934-013-0318-9.

PMID:
23568623
17.

The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.

Bibbins-Domingo K, Grossman DC, Curry SJ.

JAMA. 2017 May 16;317(19):1949-1950. doi: 10.1001/jama.2017.4413. No abstract available.

PMID:
28397958
18.

PSA test not recommended by Canadian Task Force.

Tanday S.

Lancet Oncol. 2014 Dec;15(13):e589. doi: 10.1016/S1470-2045(14)71111-8. Epub 2014 Oct 31. No abstract available.

PMID:
25499287
19.

Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.

Sammon JD, Abdollah F, Choueiri TK, Kantoff PW, Nguyen PL, Menon M, Trinh QD.

JAMA. 2015 Nov 17;314(19):2077-9. doi: 10.1001/jama.2015.7273. No abstract available.

PMID:
26575066
20.

Risks of PSA screening now better understood.

Peres J.

J Natl Cancer Inst. 2013 Nov 6;105(21):1590-2. doi: 10.1093/jnci/djt328. Epub 2013 Oct 18. No abstract available.

PMID:
24142893

Supplemental Content

Support Center